Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.38% | 41.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.88% | 29.13% | |||
| Operating Income | -56.88% | -29.13% | |||
| Income Before Tax | -77.04% | -18.82% | |||
| Income Tax Expenses | -61.29% | -- | |||
| Earnings from Continuing Operations | -75.82% | -19.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -75.82% | -19.88% | |||
| EBIT | -56.88% | -29.13% | |||
| EBITDA | -56.90% | -29.15% | |||
| EPS Basic | -75.69% | 75.99% | |||
| Normalized Basic EPS | -76.98% | 76.20% | |||
| EPS Diluted | -75.69% | 75.99% | |||
| Normalized Diluted EPS | -76.98% | 76.20% | |||
| Average Basic Shares Outstanding | 0.06% | 399.26% | |||
| Average Diluted Shares Outstanding | 0.06% | 399.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||